Financial Performance - Revenue for Q1 2025 was approximately $2.28 million, a 5.9% increase from $2.15 million in Q1 2024, driven by select price increases[1] - Gross profit increased to approximately $1.6 million in Q1 2025, representing a 28.5% increase from $1.2 million in Q1 2024, with gross margins improving to 68.5% from 56.4%[1] - The company reported a net loss of $1.85 million in Q1 2025, an improvement from a net loss of $4.63 million in Q1 2024[10] Operating Expenses and Cash Flow - Total operating expenses decreased to $4.8 million in Q1 2025, a 19% reduction from $5.9 million in Q1 2024, primarily due to a $0.8 million decrease in selling expenses[1] - Cash used in operations was $3.1 million in Q1 2025, a 30% reduction from $4.4 million in Q1 2024, reflecting improved cost control[1] Balance Sheet and Liquidity - Current liabilities decreased by $1.7 million, or 30.1%, to $3.8 million as of March 31, 2025, from $5.5 million as of December 31, 2024[1] - Cash on hand increased to $3.3 million as of March 31, 2025, compared to $1.8 million as of December 31, 2024[1] Sales and Leadership - The new leadership team has focused on improving sales productivity, achieving a 94% increase in revenue per full-time equivalent salesperson compared to Q1 2024[1] Research and Development - The company is committed to an aggressive R&D timeline for ENDOInform™, with material updates expected by the end of 2025[2] - Aspira is developing a non-invasive test for endometriosis, aiming to enhance the sensitivity and specificity of current tests by combining microRNA and protein biomarkers with patient data[5]
Aspira Women’s Health (AWH) - 2025 Q1 - Quarterly Results